Skip to main navigation Skip to search Skip to main content

Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Stereotactic body radiation therapy (SBRT) is a very effective way to treat early stage non-small cell lung cancer (NSCLC) and small oligometastatic lung lesions with consistently high rates of local control, but both local and regional/distant recurrences still occur. The management of recurrences remains unsettled and may entail repeat SBRT, conventionally fractionated external beam RT (EF-EBRT), chemotherapy or surgery. Most patients with local recurrences [within the initial planning target volume (PTV)] can be salvaged successfully with good cancer specific survival. Nonetheless, proximity of the initial SBRT delivery to organs at risk (ribs, blood vessels, airways) may make retreatment more difficult. With attention to detail and careful patient selection, both surgery and reirradiation can be performed safely and effectively. Strategies for management of regional (nodal) recurrences may require conventional therapies tailored to the patterns of failure. The role of immunotherapy in salvage has not been elucidated as yet. We review here data on the available literature concerning salvage of SBRT lung patients.

Original languageEnglish
Pages (from-to)S213-S221
JournalTranslational Lung Cancer Research
Volume8
DOIs
StatePublished - Sep 1 2019

Bibliographical note

Publisher Copyright:
© Translational lung cancer research. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Failure
  • Salvage
  • Stereotactic body radiation therapy (SBRT)

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy'. Together they form a unique fingerprint.

Cite this